| Capecitabine as adjuvant treatment for stage III colon cancer C Twelves, A Wong, MP Nowacki, M Abt, H Burris III, A Carrato, J Cassidy, ... New England Journal of Medicine 352 (26), 2696-2704, 2005 | 1691 | 2005 |
| Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J O’Shaughnessy, D Miles, S Vukelja, V Moiseyenko, JP Ayoub, ... Journal of clinical oncology 20 (12), 2812-2823, 2002 | 1440 | 2002 |
| Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study E Van Cutsem, C Twelves, J Cassidy, D Allman, E Bajetta, M Boyer, ... Journal of Clinical Oncology 19 (21), 4097-4106, 2001 | 1328 | 2001 |
| Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study J Cortes, J O'Shaughnessy, D Loesch, JL Blum, LT Vahdat, K Petrakova, ... The Lancet 377 (9769), 914-923, 2011 | 1274 | 2011 |
| Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of … PA Vasey, SB Kaye, R Morrison, C Twelves, P Wilson, R Duncan, ... Clinical cancer research 5 (1), 83-94, 1999 | 989 | 1999 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 950 | 2018 |
| Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients HR Ali, E Provenzano, SJ Dawson, FM Blows, B Liu, M Shah, HM Earl, ... Annals of oncology 25 (8), 1536-1543, 2014 | 811 | 2014 |
| XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Cassidy, J Tabernero, C Twelves, R Brunet, C Butts, T Conroy, ... Journal of Clinical Oncology 22 (11), 2084-2091, 2004 | 727 | 2004 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 662 | 2021 |
| First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin J Cassidy, C Twelves, E Van Cutsem, P Hoff, E Bajetta, M Boyer, R Bugat, ... Annals of oncology 13 (4), 566-575, 2002 | 647 | 2002 |
| Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an … PA Kaufman, A Awada, C Twelves, L Yelle, EA Perez, G Velikova, ... Journal of clinical oncology 33 (6), 594, 2015 | 490 | 2015 |
| Targeting the protein kinase C family: are we there yet? HJ Mackay, CJ Twelves Nature Reviews Cancer 7 (7), 554-562, 2007 | 481 | 2007 |
| Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study E Van Cutsem, M Findlay, B Osterwalder, W Kocha, D Dalley, R Pazdur, ... Journal of Clinical Oncology 18 (6), 1337-1345, 2000 | 422 | 2000 |
| Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade A Samson, KJ Scott, D Taggart, EJ West, E Wilson, GJ Nuovo, S Thomson, ... Science translational medicine 10 (422), eaam7577, 2018 | 365 | 2018 |
| Oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial W Scheithauer, J McKendrick, S Begbie, M Borner, WI Burns, HA Burris, ... Annals of Oncology 14 (12), 1735-1743, 2003 | 359 | 2003 |
| Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer LW Seymour, DR Ferry, DJ Kerr, D Rea, M Whitlock, R Poyner, C Boivin, ... International journal of oncology 34 (6), 1629-1636, 2009 | 337 | 2009 |
| Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. M Mackean, A Planting, C Twelves, J Schellens, D Allman, B Osterwalder, ... Journal of Clinical Oncology 16 (9), 2977-2985, 1998 | 313 | 1998 |
| Oral cancer treatment: developments in chemotherapy and beyond VJ O'neill, CJ Twelves British journal of cancer 87 (9), 933-937, 2002 | 309 | 2002 |
| Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype A Sparreboom, H Gelderblom, S Marsh, R Ahluwalia, R Obach, P Principe, ... Clinical Pharmacology & Therapeutics 76 (1), 38-44, 2004 | 299 | 2004 |
| A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days C Benson, J White, J De Bono, A O'Donnell, F Raynaud, C Cruickshank, ... British journal of cancer 96 (1), 29-37, 2007 | 289 | 2007 |
